共 99 条
[1]
Stein RL(2014)Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options Ann Hematol 93 1965-1976
[2]
Moliterno AR(2005)Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2224-2232
[3]
Tiu RV(2008)A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood 111 3383-3387
[4]
Marchioli R(2008)Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China Int J Hematol 88 530-535
[5]
Finazzi G(2009)Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients Br J Haematol 146 504-509
[6]
Landolfi R(2010)A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications Leukemia 24 1574-1579
[7]
Kutti J(2007)Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092-1097
[8]
Gisslinger H(2008)Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment Leukemia 22 437-438
[9]
Patrono C(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 452-458
[10]
Marilus R(undefined)undefined undefined undefined undefined-undefined